Home › NDC Lookup › Ingredients › Gentamicin Sulfate › 24208-0580-60
Gentamicin Sulfate 3 mg/mL Solution/ Drops — NDC 24208-0580-60 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Gentamicin Sulfate 3 mg/mL Solution/ Drops — NDC 24208-580-60 (Billing 24208-0580-60)

by Bausch & Lomb Incorporated · 1 BOTTLE, DROPPER in 1 CARTON / 5 mL in 1 BOTTLE, DROPPER

This is a package of Gentamicin Sulfate 3 mg/mL Solution/ Drops from Bausch & Lomb Incorporated, marketed since May 1994 and currently FDA-listed; retail pharmacies pay about $0.7900 per mL (NADAC). It is this product's only package size.

NDC 24208-0580-60
🏷️ FDA NDC (as labeled) 24208-580-60 billing pads the product segment with a zero
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 24208-580-60
Product NDC 24208-580
11-digit billing NDC 24208058060
NCPDP billing unit ML — per mL (volume)
RxCUI 310467
UNII 8X7386QRLV
Application # ANDA064048
SPL Set ID 41d01350-5c4b-42fc-be5f-986ceec02bd3
Established class (EPC) Aminoglycoside Antibacterial
Chemical class Aminoglycosides
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 1994-05-11
Route OPHTHALMIC
Dosage form SOLUTION/ DROPS
Substance GENTAMICIN SULFATE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 86101030002005
GPI class Gentamicin Sulfate
GCN Seq No 007984
GCN 33600
HICL code 004032
Ingredient (HICL) Gentamicin Sulfate
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q6
Therapeutic class — intermediate (HIC2) Ophthalmic Preparations
HIC3 code Q6W
Therapeutic class — specific (HIC3) Ophthalmic Antibiotics
AHFS code 08:12.02.00
AHFS class Aminoglycoside Antibiotics
FDB label name GENTAMICIN 0.3% EYE DROP
FDB brand name Gentamicin Sulfate
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007984
  • GCN: 33600
  • GPI-14 (Medi-Span): 86101030002005
  • HICL (First Databank): 004032
  • AHFS class code: 08:12.02.00
  • RxCUI (RxNorm): 310467
Why two NDCs? The FDA registers this code as 24208-580-60 — a 5-3-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the product segment → 24208-0580-60. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Aminoglycoside Antibacterial class.

Pharmacologic class Aminoglycoside Antibacterial
Drug family (ATC) Other antibiotics for topical use, Other aminoglycosides, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name GENTAMICIN 0.3% EYE DROP Ingredient Gentamicin Sulfate
📖 What it is MedlinePlus · NLM

Ophthalmic gentamicin is used to treat certain eye infections. Gentamicin is in a class of medications called antibiotics. It works by killing the bacteria that cause infection.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats bacterial infections of the eye and nearby structures. That includes conjunctivitis, keratitis, corneal ulcers, blepharitis and tear-sac infections, when caused by bacter...
  • What is gentamicin eye medicine used for?
  • You put one or two drops into the affected eye(s), usually about every four hours. For severe infections, your prescriber may have you use it more often. Follow your prescriber's d...
  • Burning or irritation when the drops go in is the most common, along with some eye redness or irritation. These are usually local to the eye. Call your doctor if your eye gets wors...
📖 Read our full Gentamicin Ophthalmic guide →
8
Nutrient depletion considerations

Gentamicin (IV) may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $0.790 $3.95 / 5 ml
Medicaid paysCMS SDUD · 12 mo $2.25 $11.23 / 5 ml
Medicare drug plans payPart D · Q2 2026 $1.94 $9.69 / 5 ml
NADAC price history (per mL) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $1.195 $0.590
▲ Up 21% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
24208-0580-60 You're viewing this Main listing 1 BOTTLE, DROPPER in 1 CARTON / 5 mL in 1 BOTTLE, DROPPER 1994-05-11 — Active

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Gentamicin Sulfate 3 mg/mLthis 24208-0580-60 Bausch 1 bottle $0.790 AT Availability likely —
Gentamicin Sulfate 3 mg/mL 61314-0633-05 Sandoz 5 ml $0.790 AT Availability likely —
Gentamicin Sulfate 3 mg/mL 50090-0569-00 A-S 1 bottle — AT FDA listed —
gentamicin sulfate 3 mg/mL 61919-0106-05 DIRECT 5 ml — — FDA listed —
Gentamicin Sulfate 3 mg/mL 63187-0560-05 Proficient 1 bottle — AT FDA listed —
Gentamicin Sulfate 3 mg/mL 63187-0764-05 Proficient 1 bottle — — FDA listed —
Gentamicin Sulfate 3 mg/mL 66267-0971-05 NuCare 1 bottle — — FDA listed —
Gentamicin Sulfate 3 mg/mL 68071-3554-05 NuCare 1 bottle — AT FDA listed —
Gentamicin Sulfate 3 mg/mL 68071-4775-05 NuCare 5 ml — AT FDA listed —
Gentamicin Sulfate 3 mg/mL 68071-4827-05 NuCare 5 ml — — FDA listed —
Gentamicin Sulfate 3 mg/mL 68788-8592-05 Preferred 1 bottle — AT FDA listed —
Gentamicin Sulfate 3 mg/mL 71205-0333-05 Proficient 5 ml — AT FDA listed —
Gentamicin Sulfate Opth Solution 3 mg/mL 72189-0359-05 Direct_Rx 5 ml — AT FDA listed —
Gentamicin Sulfate 3 mg/mL 76420-0137-05 Asclemed 5 ml — AT FDA listed —
Gentamicin Sulfate 3 mg/mL 76420-0254-05 Asclemed 1 bottle — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
1994
On the market since
May 1994
📍
2026
Currently FDA-listed
32 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII F5UM2KM3W7
    Benzalkonium chloride is a chemical compound that works as a preservative and antimicrobial agent in medications. It prevents bacterial and fungal growth in liquid formulations to keep the product safe during storage and use.
  • UNII QTT17582CB
    A strong acid used to adjust and maintain the proper pH level in liquid medicines, ensuring stability and preventing breakdown of active ingredients.
  • UNII 451W47IQ8X
    Sodium chloride is common table salt. It's used in medicines as a buffer to maintain proper pH, as a filler to add bulk, or to adjust the osmotic balance in liquid formulations.
  • UNII 55X04QC32I
    A strong alkaline chemical used to adjust and maintain the pH balance of liquid medicines. It helps keep the medicine stable and ensures it stays effective during storage.
  • UNII GR686LBA74
    Sodium phosphate, dibasic is a salt derived from phosphoric acid. It acts as a buffer to help maintain the medicine's pH balance and may serve as a binder or filler in tablets and capsules.
  • UNII 3980JIH2SW
    A salt form of phosphoric acid that acts as a buffer and pH adjuster in medicines. It helps keep the product at the correct acidity level for stability and effectiveness.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

7 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerBausch & Lomb Incorporated
Application holderBAUSCH AND LOMB INC
FDA applicationANDA064048 (ANDA)
Labeler code24208
First marketedMay 1994
Product typeHuman Prescription Drug
Portfolio92 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 60 words ▾

INDICATIONS AND USAGE Gentamicin sulfate ophthalmic solution is indicated in the topical treatment of ocular bacterial infections including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

⏱️ Dosage and Administration 30 words ▾

DOSAGE AND ADMINISTRATION Instill one or two drops into the affected eye(s) every four hours. In severe infections dosage may be increased to as much as two drops every hour.

⛔ Contraindications 17 words ▾

CONTRAINDICATIONS Gentamicin sulfate ophthalmic solution is contraindicated in patients with known hypersensitivity to any of its components.

⚠️ Warnings 34 words ▾

WARNINGS NOT FOR INJECTION INTO THE EYE Gentamicin sulfate ophthalmic solution is not for injection. It should never be injected subconjunctivally, nor should it be directly introduced into the anterior chamber of the eye.

🤒 Adverse Reactions 69 words ▾

ADVERSE REACTIONS Bacterial and fungal corneal ulcers have developed during treatment with gentamicin ophthalmic preparations. The most frequently reported adverse reactions are ocular burning and irritation upon drug instillation, non-specific conjunctivitis, conjunctival epithelial defects and conjunctival hyperemia. Other adverse reactions which have occurred rarely are allergic reactions, thrombocytopenic purpura and hallucinations.

To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

🤰 Pregnancy 64 words ▾

Pregnancy Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women. Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

🧬 Clinical Pharmacology 39 words ▾

CLINICAL PHARMACOLOGY Microbiology Gentamicin sulfate is active in vitro against many strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens.

📦 How Supplied / Storage and Handling 106 words ▾

HOW SUPPLIED Gentamicin sulfate ophthalmic solution USP, 0.3% is supplied sterile in a white LDPE plastic bottle, with a white LLDPE extended controlled drop tip and white polypropylene cap in the following size: NDC 24208-580-60 - 5 mL NOT FOR INJECTION INTO THE EYE FOR OPHTHALMIC USE ONLY Storage: Store between 2°C to 25°C (36°F to 77°F). Avoid exposure to excessive heat. KEEP OUT OF REACH OF CHILDREN.

Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA © 2022 Bausch & Lomb Incorporated or its affiliates Revised: September 2022 9116006 (Folded) 9116106 (Flat) donotuse

📋 Description 126 words ▾

DESCRIPTION Gentamicin sulfate ophthalmic solution, USP is a sterile, aqueous solution buffered to approximately pH 7.0 and formulated for ophthalmic use. Each mL contains: Active: gentamicin sulfate, USP (equivalent to 3 mg gentamicin). Inactives: dibasic sodium phosphate, sodium chloride, monobasic sodium phosphate, purified water.

Hydrochloric acid and/or sodium hydroxide may be added to adjust pH (6.5 - 7.5). Preservative: benzalkonium chloride 0.01%. Gentamicin is an aminoglycoside antibiotic obtained from cultures of Micromonospora purpurea .

It is a mixture of the sulfate salts of gentamicin C1, C2, C1a and C2a. All three components appear to have similar antimicrobial activity. Gentamicin sulfate occurs as a white to buff powder and is soluble in water and insoluble in alcohol.

The structural formula is as follows: Gentamicin Sulfate (structural formula)

💬 Information for Patients 19 words ▾

Information for Patients To avoid contamination, do not touch tip of container to the eye, eyelid or any surface.

⚠️ Precautions 177 words ▾

PRECAUTIONS General Prolonged use of topical antibiotics may give rise to overgrowth of nonsusceptible organisms including fungi. Bacterial resistance to gentamicin may also develop. If purulent discharge, inflammation or pain becomes aggravated, the patient should discontinue use of the medication and consult a physician.

If irritation or hypersensitivity to any component of the drug develops, the patient should discontinue use of this preparation and appropriate therapy should be instituted. Information for Patients To avoid contamination, do not touch tip of container to the eye, eyelid or any surface. Carcinogenesis, Mutagenesis, Impairment of Fertility There are no published carcinogenicity or impairment of fertility studies on gentamicin.

Aminoglycoside antibiotics have been found to be non-mutagenic. Pregnancy Gentamicin has been shown to depress body weights, kidney weights and median glomerular counts in newborn rats when administered systemically to pregnant rats in daily doses approximately 500 times the maximum recommended ophthalmic human dose. There are no adequate and well-controlled studies in pregnant women.

Gentamicin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 25 words ▾

Carcinogenesis, Mutagenesis, Impairment of Fertility There are no published carcinogenicity or impairment of fertility studies on gentamicin. Aminoglycoside antibiotics have been found to be non-mutagenic.

📄 Package Label / Principal Display Panel 27 words ▾

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 24208-580-60 Gentamicin Sulfate Ophthalmic Solution, USP 0.3% (Sterile) FOR OPHTHALMIC USE ONLY Rx only 5 mL BAUSCH + LOMB 9531303 AB07707 CARTON

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
27.1K
Units reimbursed last 4 qtrs
145.3K
Gross reimbursed last 4 qtrs
$326.2K
Avg / prescription
$12.03
Avg / unit
$2.2450
Latest quarter Q1 2026
5.8KRx
Medicaid pays / mL
$2.2450
gross reimbursed
vs
NADAC / mL
$0.7900
acquisition cost
=
Spread
+$1.4550
+184% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
36% FFS 64% MCO
Fee-for-service · 9,684 Rx Managed care · 17,432 Rx
State Medicaid map
Alaska: 80 units · 10.9 per 100k residents AK Maine: no data reported ME Washington: 3,245 units · 41.5 per 100k residents WA Idaho: 720 units · 36.7 per 100k residents ID Montana: 404 units · 35.7 per 100k residents MT North Dakota: 140 units · 17.9 per 100k residents ND Minnesota: 745 units · 13.0 per 100k residents MN Wisconsin: 1,445 units · 24.5 per 100k residents WI Michigan: 3,295 units · 32.8 per 100k residents MI New York: 7,250 units · 37.0 per 100k residents NY Vermont: 70 units · 10.8 per 100k residents VT New Hampshire: 60 units · 4.3 per 100k residents NH Oregon: 1,240 units · 29.3 per 100k residents OR Nevada: 1,290 units · 40.4 per 100k residents NV Wyoming: 400 units · 68.5 per 100k residents WY South Dakota: 257 units · 28.0 per 100k residents SD Iowa: 1,824 units · 56.9 per 100k residents IA Illinois: 3,790 units · 30.2 per 100k residents IL Indiana: 1,085 units · 15.8 per 100k residents IN Ohio: 2,980 units · 25.3 per 100k residents OH Pennsylvania: 2,510 units · 19.4 per 100k residents PA New Jersey: 1,278 units · 13.8 per 100k residents NJ Massachusetts: no data reported MA California: 24,920 units · 64.0 per 100k residents CA Utah: 180 units · 5.3 per 100k residents UT Colorado: 1,405 units · 23.9 per 100k residents CO Nebraska: 895 units · 45.2 per 100k residents NE Missouri: 3,445 units · 55.6 per 100k residents MO Kentucky: 4,836 units · 107 per 100k residents KY West Virginia: 2,840 units · 160 per 100k residents WV Virginia: 1,380 units · 15.8 per 100k residents VA Maryland: 905 units · 14.6 per 100k residents MD Connecticut: 150 units · 4.1 per 100k residents CT Rhode Island: no data reported RI Arizona: 4,340 units · 58.4 per 100k residents AZ New Mexico: 2,521 units · 119 per 100k residents NM Kansas: 735 units · 25.0 per 100k residents KS Arkansas: 3,290 units · 107 per 100k residents AR Tennessee: 205 units · 2.9 per 100k residents TN North Carolina: 2,630 units · 24.3 per 100k residents NC South Carolina: 1,580 units · 29.4 per 100k residents SC Delaware: no data reported DE Oklahoma: 2,985 units · 73.6 per 100k residents OK Louisiana: 5,830 units · 127 per 100k residents LA Mississippi: 5,857 units · 199 per 100k residents MS Alabama: 3,170 units · 62.1 per 100k residents AL Georgia: 4,435 units · 40.2 per 100k residents GA D.C.: no data reported DC Hawaii: 370 units · 25.8 per 100k residents HI Texas: 16,300 units · 53.4 per 100k residents TX Florida: 5,545 units · 24.5 per 100k residents FL
Units reimbursed · per 100k residents
2.9199
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Mississippi 199 /100k
2 West Virginia 160 /100k
3 Louisiana 127 /100k
4 New Mexico 119 /100k
5 Arkansas 107 /100k
6 Kentucky 107 /100k
7 Oklahoma 73.6 /100k
8 Wyoming 68.5 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Gentamicin Sulfate — the program that covers self-administered drugs. 10 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Gentamicin Sulfate. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$3.25M
Claims incl. refills
100.3K
Beneficiaries
78.4K
Spend / beneficiary
$41.48
Spend / claim
$32.41
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.